Last reviewed · How we verify
Crixivan (INDINAVIR)
Crixivan blocks the replication of HIV by inhibiting the protease enzyme, which is essential for the virus to produce new particles.
Crixivan (indinavir) is a small molecule drug developed by Merck Sharp Dohme, targeting the Cytochrome P450 3A4 enzyme. It is an off-patent medication used to treat human immunodeficiency virus (HIV) infection, with a short half-life of 1.0 hours and moderate bioavailability of 65%. Although it is no longer patented, Crixivan remains a commercial product under the ownership of Merck Sharp Dohme. As an HIV protease inhibitor, it works by blocking the replication of the virus, preventing the production of new viral particles. Despite its off-patent status, Crixivan's commercial availability is limited due to the absence of generic manufacturers.
At a glance
| Generic name | INDINAVIR |
|---|---|
| Sponsor | Merck & Co. |
| Drug class | indinavir |
| Target | Cytochrome P450 3A4 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | discontinued |
| First approval | 1996 |
Mechanism of action
Mechanism of Action:. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Indinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles.
Approved indications
- Human immunodeficiency virus infection
Common side effects
- Abdominal pain
- Nausea
- Diarrhea
- Vomiting
- Fever
- Malaise
- Asthenia/fatigue
- Back pain
- Headache
- Dizziness
- Somnolence
- Pruritus
Drug interactions
- CYP3A4 Substrates
- alfentanil
- bosentan
- crizotinib
- delavirdine
- itraconazole
- ixabepilone
- ketoconazole
- lovastatin
- maraviroc
- methylergometrine
- methysergide
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2,PHASE3)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2,PHASE3)
- A Prospective Cohort of Children With HIV Infection
- Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma (PHASE2)
- Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children (PHASE2,PHASE3)
- A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Crixivan CI brief — competitive landscape report
- Crixivan updates RSS · CI watch RSS
- Merck & Co. portfolio CI